London, UK-based Optimum Strategic Communications has been appointed by RNAi-focused Silence Therapeutics.
Working with US strategic partner Burns McClellan, the healthcare communications group will develop and implement an investor relations and corporate communications programme for Silence Therapeutics.
Commenting on the appointments, Ali Mortazavi, chief executive officer of Silence Therapeutics, said: “We wanted to work with a partner that could help us raise our profile in global investment community and build our reputation in the global life science industry.
“With its market-leading media relations expertise and unrivalled investor relations contacts, Optimum is the ideal partner to help us communicate our compelling equity story to the right healthcare investors.”
Since its launch in October 2017, Optimum has won over 20 clients in the life science and healthcare sectors.
Mary Clark, managing director of Optimum, said: “This is an exceptionally exciting time for Optimum and we are very excited to be working with Silence Therapeutics, which joins our growing client list of innovative and ambitious healthcare companies in the UK and across Europe.
“Our team’s knowledge of the global healthcare industry, combined with our understanding of the investor universe, enables us to provide our clients with an integrated service to help them achieve their goals.”